Clinical trials: Imipenem
Enterobacteriaceae Infections
Effect of Imipenem and Meropenem on the Digestive Microbiota and the Emergence and Carriage of Multidrug-resistant Bacteria
Among enterobacteria, ESBL production is the leading cause of multidrug resistance. The first cases of ESBL-producing Enterobacteriaceae (EBLSE) infections were described in the 1980s and subsequently spread worldwide.
- Trial name
- MERIMI (NCT05516433)
- Where
- 2 sites in France
- Volunteers
- 100 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Ventilator-Associated Pneumonia
The Population Pharmacokinetics of Imipenem in Patients With Ventilator-associated Pneumonia
This is prospective, randomized and crossover design to assess the pharmacokinetic and pharmacodynamics of three regimen. 0.5-hr infusion of imipenem 0.5 g every 6 hrs 2-hr infusion of imipenem 0.5 g every 6 hrs 2-hr infusion of…
- Trial name
- NCT01489124
- Testing
- Imipenem
- Where
- Thailand
- Volunteers
- 9 people
- Sponsor
- Sutep Jaruratanasirikul
Bacterial Infections
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of XNW4107 Alone or in Combination With Imipenem/Cilastatin
This is a 3-part, first-in-human study to evaluate the safety, tolerability and pharmacokinetics of escalating doses of XNW4107 given as intravenous (IV) infusion in healthy male subjects.
- Trial name
- NCT04482569
- Testing
- XNW4107
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Evopoint Biosciences Inc.
Infections, Urinary Tract
GSK2251052 in Complicated Urinary Tract Infection
This study is being conducted to evaluate the safety, efficacy (clinical and microbiological), pharmacokinetics/pharmacodynamics of GSK2251052 and to assess whether it would be a suitable antibiotic for the treatment for febrile…
- Trial name
- NCT01381549
- Testing
- GSK2251052, imipenem-cilastatin
- Where
- 24 sites in United States, Canada and 4 more
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline
Bacterial Pneumonia
Study Evaluating Tigecycline Versus Imipenem/Cilastatin in Hospital-Acquired Pneumonia
To compare the efficacy and safety of the tigecycline regimen with that of the imipenem/cilastatin regimen in subjects with nosocomial pneumonia.
- Trial name
- NCT00080496
- Testing
- Tigecycline, Imipenem, Cilastatin
- Where
- 29 sites in United States
- Volunteers
- 430 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Sepsis
Imipenem/Cilastatin/Relebactam PK in ECMO
Extracorporeal membrane oxygenation (ECMO) is a from of cardiopulmonary life-support for critically ill patients where blood is extracted from the vascular system and circulated by a mechanical pump while it is oxygenated and…
- Trial name
- NCT04493151
- Testing
- Imipenem, Cilastatin and Relebactam
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Joseph L. Kuti, PharmD
Bacterial Infections
Pharmacokinetics of XNW4107 in Subjects With Various Degrees of Renal Function
This is a Phase 1, open-label study to assess the PK, safety and tolerability of XNW4107, imipenem and cilastatin administered by 60-minute (60-min) IV infusion to adults with various degrees of renal insufficiency as compared to…
- Trial name
- NCT04787562
- Testing
- XNW4107, Imipenem/Cilastatin
- Where
- 2 sites in United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Evopoint Biosciences Inc.
Acinetobacter Bacteraemia
Imipenem and Sulbactam in the Treatment of Imipenem-resistant Acinetobacter Baumannii Bacteremia
Infections caused by imipenem-resistant Acinetobacter baumannii are associated with high mortality and morbidity. The treatment choices for this resistant pathogen are limited.
- Trial name
- NCT01374256
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Intra-abdominal Infections
Study of the Safety, Tolerability, and Efficacy of Relebactam (MK-7655) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone to Treat Complicated Intra-Abdominal Infection [cIAI] (MK-7655-004)
The purpose of this study is to evaluate the efficacy, safety and tolerability of adding 125 mg or 250 mg doses of relebactam (MK-7655) to imipenem/cilastatin in adults 18 years or older with Complicated Intra-Abdominal Infection…
- Trial name
- NCT01506271
- Testing
- Relebactam 250 mg, Relebactam 125 mg, Imipenem/cilastatin
- Volunteers
- 351 people
- Sponsor
- Merck Sharp & Dohme LLC
Complicated Urinary Tract Infection, Acute Pyelonephritis
Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis
Phase 3 study to evaluate the efficacy and safety of cefepime/nacubactam or aztreonam/nacubactam compared to imipenem/cilastatin in the treatment of complicated urinary tract infections (cUTI) or acute uncomplicated…
- Conditions
- Complicated Urinary Tract Infection, Acute Pyelonephritis, cUTI, AP
- Trial name
- Integral-1 (NCT05887908)
- Testing
- co-administration of cefepime and nacubactam, co-administration of aztreonam and nacubactam, imipenem/cilastatin
- Where
- 61 sites in Bulgaria, China and 7 more
- Volunteers
- 614 people
- Sponsor
- Meiji Seika Pharma Co., Ltd.
Complicated Intra-abdominal Infection, Complicated Urinary Tract Infection
Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) in Japanese Participants With Complicated Intra-abdominal Infection or Complicated Urinary Tract Infection (MK-7655A-017)
The study will evaluate the efficacy and safety of imipenem+cilastatin/relebactam (IMI/REL, MK-7655A) in Japanese participants with complicated intra-abdominal infection (cIAI) or complicated urinary tract infection (cUTI).
- Trial name
- NCT03293485
- Testing
- Imipenem+Cilastatin/Relebactam
- Where
- 29 sites in Japan
- Volunteers
- 83 people
- Sponsor
- Merck Sharp & Dohme LLC
Nosocomial Pneumonia
A Study of the Safety and Effectiveness of Levofloxacin Compared With Imipenem/Cilastatin in Patients With Pneumonia Acquired During Hospitalization
The purpose of this study is to compare the safety and effectiveness of levofloxacin with imipenem/cilastatin in the treatment of hospital-acquired pneumonia
- Trial name
- NCT00236834
- Testing
- levofloxacin; imipenem/cilastitin
- Volunteers
- 438 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Spontaneous Bacterial Peritonitis
Imipenem Versus Cefepime in Spontaneous Bacterial Peritonitis and to Evaluate the Risk Factors for Treatment Failure
1. All consecutive patients with Cirrhosis and ascites admitted to ILBS (Institute of Liver \& Biliary Sciences) will be evaluated for the presence of SBP (Spontaneous Bacterial Peritonitis) by ascitic fluid examination at…
- Trial name
- NCT01852630
- Testing
- cefepime + Albumin, Imipenem + Albumin
- Where
- India
- Volunteers
- 175 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Bacterial Infections
Intrapulmonary Pharmacokinetics of XNW4107, Imipenem and Cilastatin in Healthy Subjects
This is a Phase 1, open-label, single-center study of XNW4107 and imipenem/cilastatin administered intravenously.
- Trial name
- NCT04802863
- Testing
- XNW4107, Imipenem/Cilastatin
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Evopoint Biosciences Inc.
Osteoarthritis (OA) of the Knee
Genicular Artery Embolization (GAE) vs inTra-articular Corticosteroid Injection for Osteoarthritic Knee Pain.
This study investigates genicular artery embolization (GAE) as a minimally invasive alternative to ntra-articular corticosteroid injections (IA) or treating knee osteoarthritis (OA) pain.
- Trial name
- GET-IN (NCT06929585)
- Testing
- Genicular artery embolization, Intra-articular injection with corticosteroids.
- Where
- Taiwan
- Volunteers
- 1 people
- Sponsor
- National Taiwan University Hospital
Multi-antibiotic Resistance
Use of New Antibiotics in Sweden
Antibiotic resistance is a growing global health problem of great concern, especially multidrug-resistant Gram-negative bacteria. In recent years some new antibiotics targeting these bacteria have been developed.
- Trial name
- NCT05048693
- Where
- 7 sites in Sweden
- Volunteers
- 41 people
- Sponsor
- Uppsala University
Septic Shock
The Analysis of Factors Influencing the Vd of Imipenem in Septic Shock Patients
The study measures the plasma concentrations of imipenem in septic shock patients and non-septic shock patients and observes hypoalbuminemia and the impact of the severity of critical illness on Vd
- Trial name
- NCT03308214
- Testing
- Imipenem
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Southeast University, China
Ventilator Associated Pneumonia
Pharmacodynamics Study of Imipenem in Patients With Ventilator Associated Pneumonia
Imipenem is a carbapenem antibacterial agent with a broad spectrum of activity against Gram-negative and Gram-positive bacteria.
- Trial name
- NCT01379157
- Testing
- Imipenem
- Where
- Thailand
- Volunteers
- 8 people
- Sponsor
- Prince of Songkla University
Suspected or Documented Gram-negative Bacterial Infection
Safety, Tolerability, Efficacy and Pharmacokinetics of Imipenem/Cilastatin/Relebactam (MK-7655A) in Pediatric Participants With Gram-negative Bacterial Infection (MK-7655A-021)
The primary purpose of this study is to evaluate the safety and tolerability of imipenem/cilastatin/relebactam (IMI/REL) in participants from birth to less than 18 years of age with confirmed or suspected gram-negative bacterial…
- Trial name
- NCT03969901
- Testing
- IMI/REL, Active Control, Oral Switch
- Where
- 67 sites in United States, Bulgaria and 16 more
- Volunteers
- 115 people
- Sponsor
- Merck Sharp & Dohme LLC
MDR Bacteria
Comparing Efficacy and Safety of (Meropenem + Colistin) Versus (Imipenem/Cilastatin + Tigecycline) on Eradication of Multi-Drug Resistance Bacteria
This study aims to compare the efficacy and safety of two antibiotic combinations (Colistin + Meropenem) vs (Imipenem/cilastatin+ Tigecycline) in the treatment of adults with MDR gram-negative infections.
- Trial name
- NCT07524920
- Testing
- "Imipenem/cilastatin" and "Tigecycline", "colistin" and "meropenem"
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Ain Shams University